Canada Bio-Mfg Facility & COVID-19 reserved vaccines

---

Canada signs agreements with Pfizer, Novavax, J&J, & Moderna

• Pfizer, will supply a minimum of 20 million doses of its mRNA-based vaccine candidate, BNT162. Options for obtaining additional doses are under discussion.
• Johnson & Johnson, will supply up to 38 million doses of its vaccine candidate Ad26.COV2.S.
• Novavax, will supply up to 76 million doses of its vaccine candidate NVX-CoV2373.
• Moderna, will supply up to 56 million doses of its vaccine candidate mRNA-1273.

Minister: “Aggressive approach in procuring a portfolio of the most promising vaccine candidates”

According to the Minister of Public Services and Procurement, Anita Anand, “As we continue our work to purchase the supplies and equipment that are necessary to combat the COVID-19 pandemic, we remain equally focused on planning for the future, including securing potential vaccines for Canadians. We are taking an aggressive approach in procuring a portfolio of the most promising vaccine candidates in order to ensure that Canadians will have access to them as quickly as possible once they have been approved.”

Canada already has a $1 billion fund through the ‘Plan to Mobilize Science to fight COVID-19′ to develop a vaccine and treatments, as well as to track the virus. Of this fund, $600 million supports private sector work to develop a vaccine. See Canadian projects in chart below.

None of these vaccines have been approved as yet. They are in various stages of preliminary testing. See chart below.

According to a Canadian government statement, “Health Canada will review the evidence of safety, efficacy, and manufacturing quality for each vaccine to determine whether individual vaccines will be approved for use in Canada, before they are used to vaccinate Canadians.”

Read if you wish the standards testing should meet: COVID-19 vaccine trials should seek worthwhile efficacy Pub: 27 August 2020

 

Two Million Doses per Month Facility in Montreal at NRC

Canada will rapidly establish a new $126 million bio-manufacturing facility at the Human Health Therapeutics Research Centre (at NRC)  in Montréal.

Through a public-private partnership, the new facility according to the Canadian government “will enable the National Research Council of Canada (NRC) to increase vaccine manufacturing to up to two million doses per month by next year”.

“Canada’s Current Status in the Fight Against COVID-19: Cases leveling, CFR Remains High,” says Civil Society biostatistician.

---

June 29, 2022

Population: 38,745,871 adjusted for estimated real COVID-19 deaths

Canada	Cases	Deaths	Cured	Active
Reported:	3,948,186	41,896 1.06% CFR	3,852,879	53,411
Estimate:	21,833,469	54,464 *0.25% IFR	21,306,421	295,363

*Inferred IFR is an estimate only. The actual COVID-19 IFR may not be accurately calculated for the entire human race until long after the pandemic has ended.

Canada Provinces	Deaths	CFR%	Cases	Cured	Active
COVID-19 Totals:	41,896	1.06	3,948,186	3,852,879	53,411
* Quebec	15,572	1.43	1,087,025	1,061,417	10,036
Ontario	13,445	1.01	1,337,464	1,303,792	20,227
Alberta	4,604	0.78	587,890	574,468	8,818
BC	3,722	1.00	373,985	364,653	5,610
Manitoba	2,025	1.39	145,326	141,121	2,180
Sask	1,396	1.00	139,617	136,127	2,094
First Nations	740	0.67	110,221	108,013	1,468
NB	422	0.63	67,241	65,810	1,009
Nova Scotia	421	0.42	101,347	99,406	1,520
NL	189	0.40	47,353	46,454	710
* PEI	45	0.11	40,806	39,693	1,068
Yukon	26	0.58	4,453	4,360	67
* NWT	22	0.18	12,135	12,094	19
Nunavut	7	0.20	3,531	3,471	53
Repatriates	0		13	13	0
Sub Totals	41,896	1.06	3,948,186	3,852,879	53,411

Recoveries are estimated using a Canadian-specific algorithm. Canadian COVID-19 Data is weekly by the country. Some data CSPAC obtains from Public Health Units is updated daily.

* Quebec, * Northwest Territories, * Prince Edward Island data is current daily.
Note: Last available First Nations data is shown when provided by the federal government of Canada.

Below: Extensive Estimates using data from multiple sources.

Beta experimental estimates for Canada. Reported + unreported mild + asymptomatic COVID-19 infections.

The total actual number of infections in Canada including all the untested, unreported, asymptomatic infections is likely greater than 21,833,469 (56.35% of the population) including mild and asymptomatic cases. That would mean the estimated inferred average Infection Fatality Rate:
(IFR) is likely around 0.25%

Canadian COVID-19 deaths to 2022-06-29 are estimated to be 54,584 Using estimated IFR of 0.25% which is far below global average IFR.

54,584 (0.25% IFR) is the CSPaC estimated number of Canadian COVID-19 deaths (based on the inferred IFR) including those deaths unreported as COVID-19). The IHME estimates excess deaths in Canada to reach much higher than CSPaC estimates.

See The Lancet estimate of excess mortality from COVID-19 (Download PDF) in 191 countries/territories and 252 subnational units of select countries, from 1 January 2 0 2 0, to 31 December 2 0 2 1.

54464 Is the CSPaC estimated number of Canadian COVID-19 deaths based on a modified universal algorithm which factors more sophisticated public health infrastructure and also fewer available urgent care beds and facilities which is a problem in much of Canada in an emergency measures context.

The closeness of the two numbers derived from unique data and methods suggests their high probability. The blended data of three projections from three different biostatistician labs also confirms the estimates +/- .01%.

It is safe to say that Canadians have endured the grief of losing 54464 family members. Every number has a face. May their memory be forever a blessing to their families and friends.

Canada's advanced public health standards.

Canada and the USA both have a significantly lower than global average Infection Fatality Rate. (influenza has an IFR of .1% or 6 per 100k (2019)).

Ontario, Canada Reports

---

Ontario Regional Public Health Units (PHU) - Reported by Ontario Province.

These reports from the Ontario Provincial government differ significantly (much lower) from the data reported by individual Public Health Units (PHU). CSPaC includes links to each PHU to allow readers of this report to check the latest data from their public health unit.

---

Health Unit	Cases	Deaths	CFR	Recoveries	Active
Algoma District	8,581	57	0.7%	8,445	79
Brant County	11,873	83	0.7%	11,741	49
Chatham-Kent	8,798	92	1.0%	8,683	23
Durham Region	63,071	496	0.8%	62,295	280
Eastern Ontario	16,097	218	1.4%	15,821	58
Grey Bruce	8,873	69	0.8%	8,767	37
Haldimand-Norfolk	8,810	83	0.9%	8,685	42
Haliburton Kawartha Pine Ridge	9,498	111	1.2%	9,332	55
Halton Region	49,627	327	0.7%	49,057	243
Hamilton	58,974	571	1.0%	58,066	337
Hastings & Prince Edward Counties	10,388	63	0.6%	10,254	71
Huron Perth	7,428	111	1.5%	7,291	26
Kingston Frontenac Lennox & Addington	17,560	60	0.3%	17,298	202
Lambton County	11,903	146	1.2%	11,723	34
Leeds Grenville And Lanark District	9,567	106	1.1%	9,357	104
Middlesex-London	38,523	401	1.0%	37,964	158
Niagara Region	41,584	548	1.3%	40,829	207
North Bay Parry Sound District	6,132	44	0.7%	6,037	51
Northwestern	9,604	22	0.2%	9,266	316
Ottawa	74,552	818	1.1%	73,252	482
Oxford Elgin-St.Thomas	13,991	169	1.2%	13,767	55
Peel Region	186,616	1,356	0.7%	184,468	792
Peterborough County-City	7,607	80	1.1%	7,481	46
Porcupine	7,431	69	0.9%	7,321	41
Renfrew County And District	4,827	50	1.0%	4,744	33
Simcoe Muskoka District	46,634	438	0.9%	45,927	269
Sudbury And District	15,522	150	1.0%	15,240	132
Thunder Bay District	12,907	96	0.7%	12,640	171
Timiskaming	1,985	24	1.2%	1,946	15
Toronto	324,716	4,263	1.3%	318,653	1,800
Waterloo Region	46,756	421	0.9%	46,139	196
Wellington-Dufferin-Guelph	22,462	162	0.7%	22,193	107
Windsor-Essex County	44,224	632	1.4%	43,433	159
York Region	112,855	1,042	0.9%	111,193	620

Last Updated: 2022-06-29 Time 05:46:25 GMT. Source: CSPaC

---

Justin Trudeau, Prime Minister of Canada said Monday that, “As we continue to work together to limit the impact of the COVID-19 pandemic on the health of Canadians, as well as its social and economic effects, we must also maximize our chances of defeating the virus. To do this, we need to invest in the development of several promising vaccines and ensure that we can manufacture and distribute the vaccine to as many Canadians as possible, as quickly as possible. That is how we will move forward on a sustainable path to a full recovery.”

---

Watch Patty Hajdu, Minister of Health.

 

 

Chart: SARS2-CoV-2 vaccine candidates in Phase 1-3 plus significant candidates in pre-clinical R&D

 

Candidate	Sponsor	Trial Phase	Institution
bacTRL-Spike	Symvivo	Pre-clinical	Symvivo Corporation
PittCoVacc	UPMC/University of Pittsburgh School of Medicine	Pre-clinical	University of Pittsburgh
V591	University of Pittsburgh’s Center for Vaccine Research	Pre-clinical	University of Pittsburgh; Themis Biosciences; Institut Pasteur
Ii-Key peptide COVID-19 vaccine	Generex Biotechnology	Pre-clinical	Generex
Recombinant vaccine	Vaxart	Pre-clinical	Vaxart
LineaDNA	Takis Biotech	Pre-clinical	Takis Biotech
AdCOVID	Altimmune	Pre-clinical	University of Alabama at Birmingham
T-COVIDTM	Altimmune	Pre-clinical
Protein subunit vaccine	University of Saskatchewan Vaccine and Infectious Disease Organization-International Vaccine Centre	Pre-clinical	University of Saskatchewan Vaccine and Infectious Disease Organization-International Vaccine Centre
Adenovirus-based vaccine	ImmunityBio; NantKwest	Pre-clinical
AAVCOVID	Massachusetts Eye and Ear; Massachusetts General Hospital; University of Pennsylvania	Pre-clinical
Recombinant vaccine	Sanofi, Translate Bio	Pre-clinical
HaloVax	Voltron Therapeutics, Inc.; Hoth Therapeutics, Inc.	Pre-clinical	MGH Vaccine and Immunotherapy Center
mRNA-based vaccine	Chulalongkorn University’s Center of Excellence in Vaccine Research and Development	Pre-clinical
HDT-301	University of Washington; National Institutes of Health Rocky Mountain Laboratories; HDT Bio Corp	Pre-clinical
gp96-based vaccine	Heat Biologics	Pre-clinical	University of Miami Miller School of Medicine
ChAd-SARS-CoV-2-S	Washington University School of Medicine in St. Louis	Pre-clinical	Washington University School of Medicine in St. Louis
Inactivated vaccine	Wuhan Institute of Biological Products; China National Pharmaceutical Group (Sinopharm)	Phase 3	Henan Provincial Center for Disease Control and Prevention
CoronaVac	Sinovac	Phase 3	Sinovac Research and Development Co., Ltd.
mRNA-1273	Moderna	Phase 3	Kaiser Permanente Washington Health Research Institute
Ad5-nCoV	CanSino Biologics	Phase 3	Tongji Hospital; Wuhan, China
NVX-CoV2373	Novavax	Phase 2b	Novavax
Bacillus Calmette-Guerin (BCG) live-attenuated vaccine	University of Melbourne and Murdoch Children’s Research Institute; Radboud University Medical Center; Faustman Lab at Massachusetts General Hospital	Phase 2/3	University of Melbourne and Murdoch Children’s Research Institute; Radboud University Medical Center; Faustman Lab at Massachusetts General Hospital
AZD1222/Covishield	The University of Oxford; AstraZeneca; IQVIA; Serum Institute of India	Phase 2/3	The University of Oxford, the Jenner Institute
BNT162	Pfizer, BioNTech	Phase 2/3	Multiple study sites in Europe and North America
Adjuvant recombinant vaccine candidate	Anhui Zhifei Longcom Biopharmaceutical, Institute of Microbiology of the Chinese Academy of Sciences	Phase 2
ZyCoV-D	Zydus Cadila	Phase 2	Zydus Cadila
Covaxin	Bharat Biotech; National Institute of Virology	Phase 2
BBIBP-CorV	Beijing Institute of Biological Products; China National Pharmaceutical Group (Sinopharm)	Phase 1/2	Henan Provincial Center for Disease Control and Prevention
GRAd-COV2	Genexine	Phase 1/2
Sputnik V	Gamaleya Research Institute, Acellena Contract Drug Research and Development	Phase 1/2	Various
Self-amplifying RNA vaccine	Imperial College London	Phase 1/2	Imperial College London
LUNAR-COV19	Arcturus Therapeutics and Duke-NUS Medical School	Phase 1/2	Duke-NUS Medical School, Singapore
INO-4800	Inovio Pharmaceuticals	Phase 1/2	Center for Pharmaceutical Research, Kansas City. Mo.; University of Pennsylvania, Philadelphia
Ad26.COV2-S	Johnson & Johnson	Phase 1/2	Johnson & Johnson
mRNA-based vaccine	CureVac	Phase 1	CureVac
SCB-2019	GlaxoSmithKline, Sanofi, Clover Biopharmaceuticals, Dynavax and Xiamen Innovax	Phase 1	Linear Clinical Research (Australia)
COVAX-19	Vaxine Pty Ltd.	Phase 1	Royal Adelaide Hospital
Plant-based adjutant COVID-19 vaccine candidate	Medicago; GSK; Dynavax	Phase 1	Medicago
Molecular clamp vaccine	CSL; The University of Queensland	Phase 1
V590	Merck; IAVI	Phase 1
GRAd-COV2	ReiThera; Leukocare; Univercells	Phase 1	Lazzaro Spallanzani National Institute for Infectious Diseases
AdimrSC-2f	Adimmune	Phase 1	Adimmune
mRNA lipid nanoparticle (mRNA-LNP) vaccine	CanSino Biologics, Precision NanoSystems	Early research

 

Chart Data Source: Regulatory Affairs Professionals Society.

 

Read also:

Civil Society aims at children to demystify SARS2 vaccines